We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Miss
Francine
Heatley
f.heatley@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Venous thromboembolism
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Hospital-acquired thrombosis (HAT) is defined as any venous thromboembolism (VTE) within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key prevention strategies include extended pharmacological thromboprophylaxis (EDPTP) prescribed beyond hospital discharge and provision of graduated compression stockings (GCS). There is compelling evidence to support the use of pharmacological thromboprophylaxis, however, there is little evidence to support the use of additional GCS, which can cause complications in as many as 5% of patients. Providing GCS in this group costs the NHS a minimum of £8.3 million per annum. This study aims to establish whether:
1. Patients undergoing surgical procedures requiring EDPTP benefit from additional GCS to prevent VTE
2. Patients receiving GCS experience an increased rate of adverse events
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2025 Protocol article in https://pubmed.ncbi.nlm.nih.gov/40623749/ (added 08/07/2025)
You can take part if:
You may not be able to take part if:
1. Contraindications to EDPTP or GCS 2. Individuals requiring therapeutic anticoagulation e.g., anticoagulation for previous DVT3. Known thrombophilia or thrombogenic disorder
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Miss
Francine
Heatley
f.heatley@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Imperial College London and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR155294.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS: 60092
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
